Received Feb 18, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
headache; nausea; chills; This non-serious case was reported by a nurse via sales rep and described the occurrence of headache in a female patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced headache (Verbatim: headache), nausea (Verbatim: nausea) and chills (Verbatim: chills). The outcome of the headache, nausea and chills were resolved. The reporter considered the headache, nausea and chills to be related to Shingrix. The company considered the headache, nausea and chills to be related to Shingrix. Additional Information: GSK receipt date: 23-JAN-2025 The reporter reported that the patient had recived Shingrix vaccine and experienced headache, nausea and chills. The expiry date of 1st dose of Shingrix were unknown. The patient did not want to get second dose and the doctor wants to be advised of next steps. Physician wanted to be advised if the patient should get the second dose even though the patient had the adverse reactions reported.